McMahon Neurorestoration Lab, Wolfson CARD, School of Biomedical Sciences, King's College London, London SE1 1UL, UK.
Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK.
Nat Rev Rheumatol. 2014 Jun;10(6):374-80. doi: 10.1038/nrrheum.2014.47. Epub 2014 Apr 1.
In this article, we present the case for the existence of a subgroup of patients with osteoarthritis (OA) who experience pain with neuropathic features. Recognizing these patients as a distinct subgroup will allow clinicians to improve the management of their symptoms. We discuss the diagnostic criteria for pain to be classed as neuropathic, then systematically examine the applicability of these criteria to the symptoms, signs and pathology of OA. What are the implications for the preclinical development and clinical use of analgesics for OA? How should existing treatment options be reassessed? Differences in the aetiology of OA and the pharmacological sensitivity of patients with OA pain with neuropathic features, compared with other patients with OA, might explain the frequent negative findings of clinical trials of treatments for symptomatic OA. If the global prevalence of OA pain with neuropathic features is accurately represented by reports from small experimental groups of patients, then a substantial unmet need to tailor diagnosis and therapy for these individuals exists.
在本文中,我们提出了存在一类骨关节炎(OA)患者亚组的观点,他们经历的疼痛具有神经病理性特征。将这些患者视为一个明确的亚组,将使临床医生能够改善对其症状的管理。我们讨论了将疼痛归类为神经病理性的诊断标准,然后系统地检查这些标准对 OA 的症状、体征和病理学的适用性。这对 OA 镇痛剂的临床前开发和临床应用有何影响?应该如何重新评估现有的治疗选择?OA 的病因学差异以及与其他 OA 患者相比,OA 疼痛伴神经病理性特征患者对 OA 疼痛的药物敏感性可能解释了针对 OA 症状的治疗的临床试验中经常出现阴性结果的原因。如果 OA 疼痛伴神经病理性特征的全球患病率准确反映了来自小患者实验组的报告,那么针对这些个体进行诊断和治疗的需求尚未得到满足。